跳至主要内容
临床试验/RBR-84nmnm9
RBR-84nmnm9招募中不适用

Evaluation of the use of PET/CT with 18F-PSMA as a staging tool and potential predictor for theranostic therapy in patients diagnosed with Adenoid Cystic Carcinoma

Eduardo Nóbrega Pereira Lima0 个研究点开始时间: 2023年7月31日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18Y 至 0(—)

入选标准

  • Age above 18 years. Histological diagnostic confirmation of Neoplasia Adenoid Cystic Carcinoma (ADC). Ability to understand aspects associated with the proposed clinical study and consent to participate.Patients who have performed at least one onventional imaging (computed tomography, magnetic resonance imaging, ultrasonography, and bone scintigraphy) as part of an initial assessment of the extent of neoplastic disease or as part of a recent assessment of ongoing tumor response to CAdC neoplasia.

排除标准

  • Clinical condition that contraindicates the use of targeted imaging for staging conventional or exposure to radiopharmaceuticals such as: ongoing pregnancy, breastfeeding or any condition that the attending physician considers a risk for participation in the study.

研究者

发起方
Eduardo Nóbrega Pereira Lima

相似试验

已完成
1 期
Exploratory Study of Usefulness of 18F-BPA PET/CT in Clinical Staging of Malignanciespatients with malignancies
JPRN-UMIN000008359"Hotta Group" of National Cancer Center Cancer Research and Development Fund120
进行中(未招募)
1 期
se of 18F-PSMA-11 PET for detection of lesions in iodine refractory thyroid cancers
EUCTR2021-000456-19-BEniversity Hospital Ghent20
已完成
不适用
Clinical utility of [F-18]PSMA-1007 PET/CT (positron emission tomography/computed tomography) in evaluating preoperative staging of prostate cancer before radical prostatectomy
KCT0004476Yonsei University Health System, Severance Hospital126
进行中(未招募)
1 期
Prospective evaluation of 68Ga-PSMA PET-CT for Recurrence detection of Prostate Cancer and its impact on patient management. The ProsPERo TrialMales 18 years of age or older with histologically-proven prostate adenocarcinoma and biochemical relapse with rising PSA level after initial treatment with radical curative intent, not yet on palliative systemic treatment and considered for further salvage therapyMedDRA version: 19.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10068979Term: Imaging procedureSystem Organ Class: 10022891 - Investigations
EUCTR2016-000842-79-BEInstitut Jules Bordet75
已完成
Unknown
A retrospective study using 18F-FDG-PET/CT for the prediction of immunotherapy-related interstitial lung disease in lung cancer.Advanced or recurrent lung cancer
JPRN-UMIN000053550iigata University Medical and Dental Hospital165